SIK2 and ovarian cancer: Taken together, these data suggest that the inhibition of SIK2 kinase activity potentiates carboplatin in ovarian cancer cells, and ARN-3261, a potent SIK2 selective inhibitor, works synergistically with carboplatin to kill ovarian cancer cells.